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Background: Diabetes model projects in different regions of Germany including interventions such as quality
circles, patient education and documentation of medical findings have shown improvements of HbA1c levels,
blood pressure and occurrence of hypoglycaemia in before-after studies (without control group). In 2002 the
German Ministry of Health defined legal regulations for the introduction of nationwide disease management
programs (DMP) to improve the quality of care in chronically ill patients. In April 2003 the first DMP for patients
with type 2 diabetes was accredited. The evaluation of the DMP is essential and has been made obligatory in
Germany by the Fifth Book of Social Code. The aim of the study is to assess the effectiveness of DMP by example
of type 2 diabetes in the primary care setting of two German federal states (Rheinland-Pfalz and Sachsen-Anhalt).
Methods/Design: The study is three-armed: a prospective cluster-randomized comparison of two interventions
(DMP 1 and DMP 2) against routine care without DMP as control group. In the DMP group 1 the patients are
treated according to the current situation within the German-Diabetes-DMP. The DMP group 2 represents
diabetic care within ideally implemented DMP providing additional interventions (e.g. quality circles, outreach
visits). According to a sample size calculation a sample size of 200 GPs (each GP including 20 patients) will be
required for the comparison of DMP 1 and DMP 2 considering possible drop-outs. For the comparison with
routine care 4000 patients identified by diabetic tracer medication and age (> 50 years) will be analyzed.
Discussion: This study will evaluate the effectiveness of the German Diabetes-DMP compared to a Diabetes-
DMP providing additional interventions and routine care in the primary care setting of two different German
federal states.
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Background
Diabetes is a major and growing health care problem. The
number of diabetes patients is expected to increase glo-
bally from 135 to 300 million between 1995 and 2025
[1], the vast majority will have type 2 diabetes [2]. The
quality of care for diabetic patients in Germany was like in
many western countries criticized for more than two dec-
ades. The Expert Committee of the Government therefore
recommended in 2003 diabetes as a priority area [3]. Epi-
demiological data from primary care was mostly lacking,
although recently published data showed that perform-
ance of practices and diabetes control in patients could be
better than suggested [4-6]. Quality of care is expected to
improve within disease management programs (DMP) by
the implementation of evidence-based clinical practice,
by means of guidelines, quality circles, educational meet-
ings, outreach visits, patient education and by improving
coordination among different health care providers [7,8].
Consequently, clinical guidelines and DMPs for primary
care have been developed to improve quality and cost-
effectiveness of health care for chronic conditions such as
diabetes.
In the reform law of 2002 the German Ministry of Health
defined a complicated process for the introduction of
DMPs and on 27 February 2003 the Federal Insurance
Office accredited the first DMP for type 2 diabetes [9]. Sev-
eral patient- and provider-oriented interventions within
the German-style DMP aiming at decreasing mortality and
morbidity of patients with type 2 diabetes reducing micro-
and macrovascular complications and increasing quality
of life of diabetes patients. The underlying criteria there-
fore have been developed by the newly formed Coordi-
nating Committee and have gone through a tough process
of certification before they have been regulated by law by
the Ministry of Health in 2002 [10]. The German DMP
structure is tightly linked to financial incentives for the
sickness funds, i.e. it is linked with the risk structure com-
pensation (= RSC) which was introduced to compensate
for differences in the risk structure of the insured popula-
tion. [9]. Besides the requirement of a comprehensive
documentation and the obligation to provide guideline-
oriented healthcare the statutory health insurances are
obliged to evaluate DMPs by the Fifth Book of Social Code
[9,11].
However, until now valid scientific data showing the
effectiveness of the German Diabetes-DMP are missing.
Recently published data of diabetes model projects in the
region of Nordrhein, Sachsen-Anhalt and Baden-Wuert-
temberg show improvements of HbA1c levels, blood pres-
sure and occurrence of hypoglycaemia [12-14]. However,
the duration of these model projects was too short to draw
conclusions concerning clinical endpoints (i.e. a cardio-
vascular events, amputation rate) and bias because of the
preferred inclusion of highly motivated patients can not
be excluded [15].
Methods/Design
Aim and design of the study
The aim of the study is to assess the effectiveness of DMP
compared to routine care in the primary care setting of
two different German federal states (Rheinland-Pfalz and
Sachsen-Anhalt). Since DMPs are liable to an implemen-
tation process ongoing at the moment which is differing
considerably depending on several criteria (e.g. region of
Germany, rural/urban area, health insurance) three
groups will be observed: a "routine care group without
DMP" (= control group; CG), a "DMP real group" (= DMP
1) and a group of patients participating in an (within the
scope of the German law regulations) optimally in prac-
tices implemented DMP (= DMP 2).
The study is designed as a prospective cluster-randomized
comparison of the two intervention groups (DMP 1 and
DMP 2) against routine care as control group (Fig 1). The
cluster randomization was chosen because this has opti-
mal internal validity (absence of confounders) while
avoiding contamination of interventions associated with
patient randomisation.
Scientific hypotheses
• The German-Diabetes-DMP (DMP 1) is more effective
than routine diabetes care (CG)
• An optimally implemented form of the Diabetes-DMP
(DMP 2) is more effective than the German-Diabetes-
DMP (DMP 1).
Sample size calculation
Sample size calculations for cluster randomized trials dif-
fer from sample size calculations for common RCTs
requiring a larger number of patients. Based on the main
outcome parameters we performed a power calculation
with the Cluster Randomization Sample Size Calculator
ver.1.02 of the University of Aberdeen on the basis of an
ICC of 0,05. Considering possible drop-outs a sample size
of 200 GPs will be required (each GP including 20
patients).
Selection of participants
500 GPs in Rheinland-Pfalz and 500 GPs in Sachsen-
Anhalt participating in the Diabetes-DMP will be
recruited by an invitation letter giving information about
the study project. From those who will accept to partici-
pate, 100 GPs will be randomized in the DMP group 1
and 100 in the DMP group 2. All patients with a type 2
diabetes out of these practices insured at the general
regional health funds (Allgemeine Ortskrankenkassen =
AOK) and participating in the DMP will be included in theBMC Public Health 2005, 5:99 http://www.biomedcentral.com/1471-2458/5/99
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study then. Incomplete participation in the interventions
will be an exclusion criterion in the DMP group 2.
For the control group 4000 AOK patients out of practices
not participating in the DMP will be detected through dia-
betes tracer medication and age (> 50 years) and will be
matched. Participation in a DMP offered by another
health fund is an exclusion criterion in the control group.
Data collection and analysis
All data will be provided by the AOK. Data of the DMP
groups are retrieved by the DMP documentation forms
which have to be completed routinely every 3 to 6 months
during the scheduled DMP visits of participating patients.
The information about the tracer medication identifying
patients of the control group is also provided by the AOK.
The data reporting will follow the CONSORT recommen-
dations for cluster randomized trials [16].
Data analysis will be performed according to the inten-
tion-to-treat (ITT) method. For missing data the 'last
observation carried forward' -method will be used.
Outcome-parameter
Outcome parameters were defined considering best avail-
able evidence, legal regulations and feasibility. According
to our two scientific hypotheses two groups of outcome
parameters were defined: "outcome parameters I" for the
comparison of the DMP groups and "outcome parameters
II" for the comparison of DMP and routine care. This dif-
ferentiation of the outcome parameters is essential
because in the control group availability of patient data
will be limited to process indicators only. The outcome
parameters are displayed in Table 1.
Intervention
The minimum requirements for the Diabetes-DMP are
regulated by law and defined in the RSAV [10]. According
to the legal regulations the intervention in the DMP1
group comprises consultations at 3- or 6-months inter-
vals. During these consultations a detailed diabetes-spe-
cific anamnesis and physical examination incl. taking
blood pressure and an analysis of HbA1c are carried out.
Furthermore agreements are made concerning further
treatment, e.g. target values for HbA1c and blood pressure
and participation on patient education programs for dia-
betes or hypertension. All medical findings as well as the
current medication have to be documented within struc-
tured, standardized documentation sheets at each consul-
tation. If required a referral to a specialist (e.g.
ophthalmologist) will be arranged. Furthermore the GPs
get a special diabetes-handbook including current, evi-
dence-based information about diabetes therapy. The GPs
participating in the DMP1 group will receive no addi-
tional intervention.
There are major difficulties introducing new evidence into
general practice requiring comprehensive implementa-
tion support at different levels (patients, doctors, practice
team) [17,18]. Therefore, in the DMP 2 group implemen-
tation support at the level of doctors and practice team
will be provided. In addition to the clinical interventions
at patients level in the DMP group 1 several components
aiming at optimizing the implementation process are pro-
Study design Figure 1
Study design.BMC Public Health 2005, 5:99 http://www.biomedcentral.com/1471-2458/5/99
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vided in this group (= implementation interventions)
(Table 2).
The control group represents routine care without DMP.
There will be no intervention at all.
Timeframe of the study
The study team will start to invite GPs at the end of Sep-
tember 2005. After receiving a written declaration of their
willingness to participate in the study and to accept
random assignment to the different groups GPs will be
randomized.
Patient inclusion and pre-data collection will start in
2005. The observation period will be 24 months.
Description of risks
Since the interventions aim at the evidence based
improvement of skills of GPs and practice teams serious
risks or undesired effects for patients are not to be
expected. There are no specific risks related to the study.
Patient informed consent
Previous to DMP participation patients already receive
written and oral information about the content and extent
of the DMP by their treating GPs, i.e. about potential ben-
efits for their health and potential risks. Furthermore,
patients are informed that DMP data including medical
data will be analyzed. In case of acceptance they have to
sign a special DMP participation form.
Ethical principles and vote of the ethics committee
The study is being conducted in accordance with medical
professional codex and the Helsinki Declaration as of
1996 as well as the German Federal Data Security Law
(BDSG). DMP participation of patients is voluntary and
can be cancelled at any time without provision of reasons
and without negative consequences for their future medi-
cal care.
The study protocol was approved by the ethics committee
of the University of Heidelberg in April 2005 (Approval-
Nr. 098-2005). Furthermore the evaluation of the DMP is
regulated by law in the Fifth Book of Social Code (§137 f.
Abs. 4 SGB V).
Data security/disclosure of original documents
The patient names and all other confidential information
fall under medical confidentiality rules and are treated
according to German Federal Data Security Law (BDSG).
Data management will be performed by the AQUA-Insti-
tute, Goettingen. All study related data are stored on a
protected central server. Only direct members of the inter-
nal study team can access the respective files. Intermediate
and final reports are stored at the office of the Department
of General Practice and Health Services Research at the
Heidelberg University Clinic.
Table 1: Primary and secondary outcome parameters
OUTCOME PARAMETERS I OUTCOME PARAMETERS II
DMP 1 vs. DMP 2 DMP 1 vs. CG
Primary outcome parameter Primary outcome parameter
Proportion of patients achieving target values for HbA1c and RR 
according to the legal regulations (10)
Proportion of patients with prescriptions for antidiabetic, 
antihypertensive and lipid-lowering drugs
Secondary outcome parameters Secondary outcome parameters
Proportion of patients with prescriptions for antidiabetic, 
antihypertensive and lipid-lowering drugs
----
Proportion of patients with referrals to ophthalmologists, specialists for 
diabetology and diabetic feet
Proportion of patients with referrals to ophthalmologists, specialists for 
diabetology and diabetic feet
Proportion of patients referred to a patient education training for diabetes 
and hypertension
Proportion of patients referred to a patient education training for diabetes 
and hypertension
Proportion of patients with severe complications (amputation, dialysis etc.) Proportion of patients with severe complications (amputation, dialysis etc.)
Proportion of patients with > 2 hospitalizations in the last 6 months Proportion of patients with > 2 hospitalizations in the last 6 months
Consultation rate Consultation rate
Days of incapacity to work Days of incapacity to work
Mean differences of HbA1c, RR, BMI and glomerular filtration rate ---
SCORE risk chart (RR, cholesterol, smoking status, age, gender) ---
Drop out rate from the DMP ---BMC Public Health 2005, 5:99 http://www.biomedcentral.com/1471-2458/5/99
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Discussion
There are specific difficulties in evaluating the effective-
ness of complex interventions such as disease manage-
ment programs [19], particularly, in our case that
implementation process has already started [15]. At the
moment it is not conceivable to which phase of the imple-
mentation process the DMP actually has preceded. How-
ever, the DMP group 2 represents an ideal
implementation of the DMP within the scope of the Ger-
man law regulation.
To adapt the evaluation design to the real conditions of
diabetes care in Germany at the moment, but also to con-
sider the ongoing implementation process we have cho-
sen the design of a prospective randomized-controlled
comparison of the two DMP groups embedded in the
quasi-experimental design of a controlled before-after
study with a blinded control group. The quasi-experimen-
tal design is predetermined because allocation to the con-
trol group can not be perfomed randomly and because
baseline values for patients participating in the DMP have
not been documented.
A fully experimental design with a randomized control
group was rejected by the authors, because this could cre-
ate an artificial care situation. That is informing patients
and GPs of the control group about the study and proba-
bly asking for completing any questionnaires would intro-
duce an enormous bias.
According to the theoretical model for design and evalua-
tion of complex interventions by Campbell et al the pre-
sented study can be assigned to phase III and IV (15, 20).
However, pilot projects have shown that an observation
period of 24 months will be too short to show significant
differences in severe clinical endpoints (i.e. amputations,
diabetic renal insufficiency, cardio-vascular events).
Therefore it was decided to have a combination of HbA1c
and blood pressure as primary endpoint in the rand-
omized part of the trail and prescriptions in the quasi-
experimental part of the trial.
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